Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/Mammalian target of rapamycin inhibitor

Molecular Cancer Therapeutics

Volumn 9, Issue 4, 2010, Pages 976-984

  Mallon, Robert ^a   Hollander, Irwin ^a   Feldberg, Larry ^a   Lucas, Judy ^a   Soloveva, Veronica ^a   Venkatesan, Aranapakam ^a   Dehnhardt, Christoph ^a   Santos, Efren Delos ^a   Chen, Zecheng ^a   Santos, Osvaldo Dos ^a   Ayral Kaloustian, Semiramis ^a   Gibbons, Jay ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PKI 402; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL GROWTH; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TISSUE LEVEL; ENZYME ASSAY; GLIOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE; TUMOR CELL LINE; TUMOR REGRESSION; TUMOR XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME ASSAYS; FORKHEAD TRANSCRIPTION FACTORS; GREEN FLUORESCENT PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; PHENYLUREA COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950810322     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0954     Document Type: Article

References (22)

1. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-619 (Pubitemid 44100518)
2. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signaling controls tumor cell growth. Nature 2006;441:424-430 (Pubitemid 44050136)
3. Kok K, Geering B, Vanhaesebroeck B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci 2009;34:115-127
4. Vanhaesebroeck B, Leevers SJ, Ahmadl K, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001;70:535-602. (Pubitemid 32662219)
5. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-5510
6. Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and In targeted therapy. Oncogene 2008;27:5477-5485
7. Yang X, LI P, Feldberg L, et al. A directly labeled TR-FRET assay for monitoring phosphoinositide-3-kinase activity. Comb Chem High Throughput Screen 2006;9:565-570 (Pubitemid 44156712)
8. Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3- quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63:375-381 (Pubitemid 36152495)
9. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sei U S A 2006;103: 1475-1479 (Pubitemid 43191190)
10. Carson JD, Van Aller G, Lehr R, et al. Effects of oncogenic p110a subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J 2008;409:519-524 (Pubitemid 351184970)
11. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothellumderived nitric oxide production by the protein kinase Akt. Nature 1999;399:597-601. 12. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by Insulin mediated by protein kinase B. Nature 1995;378:785-789 (Pubitemid 29279181)
12. Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP32ß, a mammalian homolog of CED-3, Is a CrmA-inhlbitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995;81:801-809
13. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenoifiabditis elegans cell death protein Ced-3 and mammalian interleukin-1 ß-converting enzyme. J Biol Chem 1994;269:30761-30764
14. Kwak EL, Sordella R, Bell DW, et al. Irreversible Inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005;102:7665-7670 (Pubitemid 40741028)
15. Sosman JA, Puzanov I. Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res 2006;12:2376-83s.
16. Arden KC. FoxO: linking new signaling pathways. Mol Cell 2004;14: 416-418
17. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-562
18. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway In cancer. Nat Rev Drug Discov 2009;8:627-644
19. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181 (Pubitemid 46316032)
20. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-2024 (Pubitemid 41609094)
21. Norden AD, Drappatz J, Wen PY. Novel anti-anglogenic therapies for malignant gliomas. Lancet Neurol 2008;7:1152-1160
22. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851-1863